Akeso and Summit report survival advantage for PD-1xVEGF combo over Keytruda
At the American Society of Clinical Oncology (ASCO) 2026 meeting, Akeso Biopharma and its partner Summit Therapeutics announced new survival results for their experimental PD‑1×VEGF bispecific antibody.
The data, first hinted at in early September, indicate that the combination outperformed the established checkpoint inhibitor Keytruda in the patient cohort studied.
The companies said the findings add to an expanding body of evidence supporting dual inhibition of the PD‑1 and VEGF pathways in oncology.
Detailed metrics such as hazard ratios, patient numbers, or statistical significance were not disclosed in the brief report.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Akeso details survival win for its PD-1xVEGF drug versus Keytruda”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that